You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Funded Biomarker Testing

Find an overview of funded biomarker testing in Ontario. Information listed includes diagnostic, predictive and prognostic markers, as well as a summary of testing sites.

Disponible en anglais seulement. Vous pouvez demander un version française.

Funded Biomarker Testing

40 items

Serous (high grade/advanced) endometrial carcinoma where HER2 directed therapy is being considered.

Funded Biomarker Disease Site: Endometrium
Biomarker: HER2
Testing Method:In Situ Hybridization (ISH)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Testing on advanced/metastatic breast cancer where directed therapy is being considered.

Funded Biomarker Disease Site: Breast
Biomarker: ESR1, PIK3CA
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Testing on previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) where FGFR2 directed therapy is being considered

Funded Biomarker Disease Site: Hepatobiliary
Biomarker: FGFR2
Testing Method:Sequencing
Testing Site: Hamilton Health Sciences, Hospital for Sick Children (SickKids), London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Testing to support diagnosis of nasopharyngeal carcinoma (newly diagnosed or suspected nasopharyngeal carcinoma).

Funded Biomarker Disease Site: Head and Neck
Biomarker: EBER
Testing Method:In Situ Hybridization (ISH)
Testing Site: Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Pages